Company: DNLI
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001714899-25-000066
Chunk: 204

Company: Denali Therapeutics Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 15
Chunk 204
---
001-3831110.38/9/201810.22ÜShare Purchase Agreement between the Registrant and F-star Gamma Limited, dated May 30, 2018.10-Q/A001-3831110.412/6/201810.23#Collaboration and License Agreement between registrant and Genzyme Corporation ("Sanofi"), dated October 29, 2018.10-K001-3831110.253/12/201910.24Common Stock Purchase Agreement between the Registrant and Biogen Inc., dated August 5, 2020.10-Q001-3831110.111/5/202010.25#Provisional LRRK2 Collaboration and License Agreement between the Registrant and Biogen Inc., dated August 5, 2020.10-Q001-3831110.211/5/202010.26Standstill and Stock Restriction Agreement between the Registrant and Biogen Inc., dated September 22, 2020.10-Q001-3831110.311/5/2020

177

10.27#Definitive LRRK2 Collaboration and License Agreement between the Registrant and Biogen Inc., dated October 4, 2020.10-Q001-3831110.411/5/202010.28#Definitive Right of First Negotiation, Option and License Agreement between the Registrant and Biogen Inc., dated October 6, 2020.10-Q001-3831110.511/5/202010.29#Side Letter between the Registrant and F-star Gamma Limited, dated June 30, 2021.10-Q001-3831110.18/4/202110.30#Amendment to Definitive LRRK2 Agreement and Waiver of and Amendment to Right of First Negotiation, Option, and License Agreement.10-Q001-3831110.111/7/202310.31Securities Purchase Agreement, dated February 27, 2024, by and among the Company and the Purchasers named therein8-K001-3831110.12/27/202410.32Nominating Agreement by and among the Company and Investor8-K001-3831110.22/27/202410.33Compensation Recovery Policy (“Clawback Policy”)10-K001-3831110.342/28/202410.34#Denali - Biogen Side Letter10-Q001-